Under the terms of the agreement, California-based Dynavax receives a non-exclusive license under Coley’s immunostimulatory oligonucleotide patent estate for the commercialization of Hepsilav. In addition to the initial payment, Coley is also eligible to receive up to an additional $5 million upon regulatory approvals of Hepsilav, as well as royalty payments for any future sales of the product.
In several previous clinical studies, Hepsilav has been shown to provide seroprotection against hepatitis B faster and with fewer doses than conventional hepatitis B vaccines, according to Coley. Additionally, Hepsilav has provided 100% seroprotection in all subjects who have received the full regimen, including those who are difficult-to-immunize.